



Diagnosis of Cystic Fibrosis in Screened Populations

Philip M. Farrell, MD, PhD¹, Terry B. White, PhD², Michelle S. Howenstine, MD³, Anne Munck, MD⁴,
Richard B. Parad, MD, MPH⁵, Margaret Rosenfeld, MD, MPH⁶, Olaf Sommerburg, MD⁷, Frank J. Accurso, MD⁸,
Jane C. Davies, MBChB, FRCPCH, MD⁹, Michael J. Rock, MD¹, Don B. Sanders, MD, MS¹⁰, Michael Wilschanski, MBBS¹¹,
Isabelle Sermet-Gaudelus, MD, PhD¹², Hannah Blau, MBBS¹³, Silvia Gartner, MD¹⁴, and Susanna A. McColley, MD¹⁵

Objective Cystic fibrosis (CF) can be difficult to diagnose, even when newborn screening (NBS) tests yield positive results. This challenge is exacerbated by the multitude of NBS protocols, misunderstandings about screening vs diagnostic tests, and the lack of guidelines for presumptive diagnoses. There is also confusion regarding the designation of age at diagnosis.

Study design To improve diagnosis and achieve standardization in definitions worldwide, the CF Foundation convened a committee of 32 experts with a mission to develop clear and actionable consensus guidelines on diagnosis of CF with an emphasis on screened populations, especially the newborn population. A comprehensive literature review was performed with emphasis on relevant articles published during the past decade.

Results After reviewing the common screening protocols and outcome scenarios, 14 of 27 consensus statements were drafted that apply to screened populations. These were approved by 80% or more of the participants.

Conclusions It is recommended that all diagnoses be established by demonstrating dysfunction of the CF transmembrane conductance regulator (CFTR) channel, initially with a sweat chloride test and, when needed, potentially with newer methods assessing membrane transport directly, such as intestinal current measurements. Even in babies with 2 CF-causing mutations detected via NBS, diagnosis must be confirmed by demonstrating CFTR dysfunction. The committee also recommends that the latest classifications identified in the Clinical and Functional Translation of CFTR project [<http://www.cftr2.org/index.php>] should be used to aid with CF diagnosis. Finally, to avoid delays in treatment, we provide guidelines for presumptive diagnoses and recommend how to determine the age of diagnosis. (*J Pediatr* 2017;181S:S33-44).

Cystic fibrosis (CF) is the most common life-threatening autosomal recessive disease in the US, occurring in approximately 1 in 4000 newborns.¹⁻³ Since 1989, it has become well known that CF is an ion channel disorder caused by mutations in the gene for the CF transmembrane conductance regulator (CFTR).⁴ There are more than 2000 mutations identified to date,⁵ approximately 10%-15% of which have so far been confirmed to be CF-causing alleles.⁶ There has been a surprising degree of difficulty encountered worldwide in establishing the diagnosis in a minority of cases and because of this, healthcare providers continue to be faced with uncertain cases and challenging diagnostic dilemmas. Although the diagnosis of CF has traditionally relied on recognition of characteristic clinical signs and symptoms, the increased use of prenatal population screening for maternal CF carrier status, prenatal ultrasound screening (that

From the ¹Departments of Pediatrics and Population Health Sciences, University of Wisconsin School of Medicine and Public Health, Madison, WI; ²Cystic Fibrosis Foundation, Bethesda, MD; ³Section of Pediatric Pulmonology, Allergy, and Sleep Medicine, Indiana University School of Medicine, Riley Hospital for Children, Indianapolis, IN; ⁴Centres de Ressources et de Compétences pour la Mucoviscidose, Hôpital Robert Debre, Paris, France; ⁵Department of Pediatric and Newborn Medicine, Harvard Medical School, Brigham and Women's Hospital, Boston, MA; ⁶Department of Pediatrics, Seattle Children's Research Institute, University of Washington School of Medicine, Seattle, WA; ⁷Heidelberg Cystic Fibrosis Center, Heidelberg, Germany; ⁸Children's Hospital Colorado, University of Colorado School of Medicine, Aurora, CO; ⁹Pediatric Respiriology and Experimental Medicine, Imperial College London and Pediatric Respiratory Medicine, Royal Brompton and Harefield National Health Service Foundation Trust, London, United Kingdom; ¹⁰Department of Pediatrics, Section of Pediatric Pulmonology, Allergy and Sleep Medicine, Riley Hospital for Children, Indiana University School of Medicine, Indianapolis, IN; ¹¹Pediatric Gastroenterology, Hadassah Hebrew University Medical Center, Jerusalem, Israel; ¹²Institut Necker Enfants Malades/INSERM U1151, Hôpital Necker Enfants Malades, Centres de Ressources et de Compétences pour la Mucoviscidose, Paris, France; ¹³Sackler Faculty of Medicine, Graub Cystic Fibrosis Center, Pulmonary Institute Schneider Children's Medical Center of Israel, Petah Tikva, Tel Aviv University, Tel Aviv, Israel; ¹⁴Hospital Vall d'Hebron, Barcelona, Spain; and ¹⁵Ann and Robert H. Lurie Children's Hospital of Chicago, Northwestern University Feinberg School of Medicine, Chicago, IL

Please see the author disclosures at the end of this article.

0022-3476/\$ - see front matter. © 2016 Published by Elsevier Inc.
<http://dx.doi.org/10.1016/j.jpeds.2016.09.065>

CF	Cystic fibrosis
CFFPR	CF Foundation Patient Registry
CFSPID	CF screen positive, inconclusive diagnosis
CFTR	CF transmembrane conductance regulator
CRMS	CFTR-related metabolic syndrome
FE	Fecal elastase
ICM	Intestinal current measurement
IRT	Immunoreactive trypsinogen
NBS	Newborn screening
NPD	Nasal potential difference
PAP	Pancreatitis-associated protein
PFT	Pulmonary function test VHIRT
	Very high IRT

might reveal meconium ileus, meconium peritonitis, bowel obstruction, or echogenic bowel), and newborn screening (NBS) has resulted in the routine diagnosis of asymptomatic or minimally symptomatic infants and a consequent opportunity to foster their normal growth and development. Since 2010 when nationwide CF NBS began in the US because of endorsements by the US Centers for Disease Control⁷ and the CF Foundation,⁸ the proportion of newly diagnosed patients identified through screening has progressively increased. In fact, in the US, approximately 64% of new CF diagnoses now follow positive NBS.

According to consensus guidelines developed by the CF Foundation in 2007 and published in *The Journal* in 2008,⁹ individuals identified by NBS can be diagnosed with CF by a sweat chloride value ≥ 60 mmol/L, or a level of 30-59 mmol/L if they have 2 CF-causing mutations in the *CFTR* gene. Although the vast majority of screened infants can be unequivocally diagnosed with CF by high levels of sweat chloride following a positive newborn screen,^{9,10} the decision is not clear-cut in a significant number of individuals.¹¹⁻¹³ Unclear diagnoses lead to treatment delays, persistent challenges,¹⁴ and stress and confusion for both families^{15,16} and clinicians.¹⁷ This group of infants, with varying levels of symptoms and a variety of *CFTR* mutations, has been the focus of discussions in the US and in Europe, with somewhat differing conclusions on both diagnosis and management.^{18,19} In addition, there has been a lack of international harmony regarding terminology, leading to confusion reflected in a recent article, entitled "Comparing the American and European diagnostic guidelines for cystic fibrosis: same disease, different language?"²⁰

Although treatment advances over the past several decades have raised the median predicted survival age from the midteens in the 1970s to more than 40 years of age today in the US²¹ and many countries in Europe,^{22,23} and more than 50 years in Canada²⁴ and in addition new *CFTR* modulator therapies offer great promise,²⁵ achieving optimal outcomes for all ages depends on timely and accurate diagnosis.^{26,27} Continued improvement in predicted survival requires careful attention to diagnostic recommendations. Despite efforts to reach and sustain a consensus on diagnostic criteria, however, it has become increasingly clear during the past few years that CF Foundation guidelines published in 2008 are not being used consistently and are considered obsolete by many clinicians.¹⁴

During the process of developing the 2008

guidelines, it was recognized that CF NBS introduced a new complexity and diagnostic dilemma, namely infants with abnormal screening tests because of elevated immunoreactive trypsinogen (IRT) levels but inconclusive sweat tests and/or DNA results. Some infants with a high IRT, for example, can display an initial sweat chloride level below the lowest accepted value for a potential CF diagnosis (30 mmol/L), even in the presence of 2 CF-causing mutations.^{12,28} More common, however, are infants with high IRT levels and sweat chloride levels below CF diagnostic levels who have fewer than 2 CF-causing mutations.¹² This latter scenario has led to a new diagnostic term and management guidelines, published in *The Journal*,¹⁹ in an article that created the term CFTR-related metabolic syndrome (CRMS).

In an effort to resolve the current diagnostic challenges following a positive CF NBS result, participants in the 2015 Diagnosis Consensus Conference included the following objectives in their mission: to develop revised guidelines for NBS-linked diagnosis, as well as for babies born after positive prenatal testing (ie, positive fetal diagnostic testing, including sweat test requirements and use of genetic data). Consensus recommendation statements that apply to the screened population, developed as a result of this conference²⁹ are presented in **Table I**.

The Many Potential Meanings of a Positive CF NBS Test

A positive CF newborn screen is a result that demands prompt follow-up to identify infants with CF. However, CF NBS programs vary considerably in design, and the type of NBS algorithm used to produce a positive screening result affects the positive predictive value, follow-up, and diagnostic processes. All CF NBS programs begin with detection of a high IRT level in a dried blood specimen from the newborn. In the US, this is routinely followed either by a second IRT measurement (IRT/IRT) or by use of a variety of *CFTR* mutation panels (usually 23-40 mutations³⁰) (IRT/DNA). IRT/IRT is used following approximately 10% of all US births, but its use is declining, because of lower sensitivity,³¹ delayed completion,³² and higher false-negative rate³³ compared with IRT/DNA NBS algorithms. A variation of the IRT/DNA method, called IRT/IRT/DNA, requires the demonstration of persistent hypertrypsinogenemia for 1-2 weeks before DNA is analyzed.³⁴ The time to diagnosis may be longer than in IRT/DNA programs, but a study suggests the IRT/IRT/DNA screen is more sensitive and detects fewer carriers.³⁴

Once a positive CF NBS result has been found, sweat chloride testing must be performed to establish a CF diagnosis (**Table I**, statement 3). Some CF NBS programs in the US that use IRT/IRT have added sweat testing, combined selectively with DNA analysis, for follow-up to the biomarker screening. However, requiring sweat testing of all infants with positive IRT/IRT tests can be logistically problematic, such as when the infant does not live close to an accredited sweat test facility. Performing a sweat chloride test in infants receiving neonatal intensive care, who are more likely to have high IRT values because of nonspecific pancreatic stress,³⁵ can also be challenging, either because they are preterm or <2 kg in weight (**Table I**, statement 2), are on

supplemental oxygen, or cannot leave the intensive care unit for the test. In these cases, *CFTR* mutation analysis can play a role in the initial evaluation even in CF NBS programs that measure biomarkers alone.

Most US CF NBS programs now include some form of DNA analysis in a second or third tier of screening.³⁶ The type of analysis performed depends on state laws and demographics of the population being screened,³⁷ but usually involves a panel of 23-40 of the most common CF-causing mutations. Some CF NBS programs subject the DNA to a more comprehensive genetic analysis.³⁸⁻

⁴⁰ Although a more detailed analysis can improve the detection of CF in nonwhite populations,⁴¹ it can

Table I. 2015 CF Foundation diagnosis consensus conference recommendations related to diagnosis of CF in the screened population*

Statement numbers*	Consensus statements
2	Newborns with a positive CF newborn screen, to increase the likelihood of collecting an adequate sweat specimen, should have the test performed bilaterally and when the infant weighs >2 kg, and is at least 36 wk of corrected gestational age.
3	Newborns greater than 36 wk gestation and >2 kg body weight with a positive CF newborn screen, or positive prenatal genetic test, should have sweat chloride testing performed as soon as possible after 10 d of age, ideally by the end of the neonatal period (4 wk of age).
4	In infants with presumptive CF identified through NBS, CF treatment should not be delayed while efforts to establish a diagnosis of CF are initiated.
6	In individuals presenting with a positive newborn screen, clinical features consistent with CF, or a positive family history, a diagnosis of CF can be made if the sweat chloride value is ≥ 60 mmol/L.
7	Individuals who are screen-positive and meet sweat chloride criteria for CF diagnosis should undergo <i>CFTR</i> genetic testing if the <i>CFTR</i> genotype was not available through the screening process or is incomplete.
8	In individuals with a positive newborn screen, a sweat chloride <30 mmol/L indicates that CF is unlikely.
10	Individuals presenting with a positive newborn screen, symptoms of CF, or a positive family history, and sweat chloride values in the intermediate range (30-59 mmol/L) on two separate occasions may have CF. They should be considered for extended <i>CFTR</i> gene analysis and/or <i>CFTR</i> functional analysis.
12	In individuals presenting with a positive newborn screen, symptoms of CF, or a positive family history, the identification of 2 CF-causing mutations (defined by <i>CFTR</i> 2) is consistent with a diagnosis of CF. Sweat chloride testing is necessary, though, to confirm the diagnosis.
13	The absence of detection of 2 CF-causing <i>CFTR</i> mutations does not exclude a diagnosis of CF.
14	If further CF functional testing is needed (NPD and ICM), it should be performed in a validated reference center with trained staff certified by the CF Foundation TDN or ECFS Clinical Trial Network.
15	In individuals with a positive newborn screen but variable or uncharacterized <i>CFTR</i> mutations (<2 CF-causing mutations), the diagnosis of CF can be made by demonstrating <i>CFTR</i> dysfunction (a sweat chloride ≥ 60 mmol/L or CF-typical NPD or ICM).
18	The definition of CRMS/CFSPID is an infant with a positive NBS test for CF and either: <ul style="list-style-type: none"> • A sweat chloride <30 mmol/L and 2 <i>CFTR</i> mutations, at least 1 of which has unclear phenotypic consequences OR • An intermediate sweat chloride value (30-59 mmol/L) and 1 or 0 CF-causing mutations
19	Children designated as CRMS/CFSPID should undergo at least 1 repeat sweat chloride test at CF centers with suitable expertise, such as an accredited CF center.
20	Children designated as CRMS/CFSPID should have clinical evaluation performed by CF providers to identify the minority that may develop clinical symptoms.

CTN, clinical trial network; ECFS, European CF Society; TDN, therapeutics development network.

*Adapted from Farrell et al.²⁹

also result in the detection of many more infants with unclear diagnostic results.¹³

An approach taken by some US CF NBS programs to improve sensitivity is the institution of a "safety net." (The term "failsafe" is also used,³⁶ although it must be cautioned that false-negative screening tests will still occur.) Safety net design differs between programs. In CF NBS programs using DNA analysis as a second tier of screening, if the DNA suggests CF, the infant is referred for diagnostic confirmation by sweat test. However, even if the second-tier DNA screen does not detect a panel mutation, infants with very high IRT (VHIRT) values may still be referred for diagnostic sweat chloride testing. These CF NBS programs include algorithms such as IRT/DNA/VHIRT,⁴² IRT/IRT1 \uparrow /DNA,⁴³ or IRT/DNA/IRT.⁴⁴ In all cases, sensitivity and specificity of algorithms using VHIRT must be evaluated, as has been done in New York.⁴²

The use of VHIRT as a safety net also has been used elsewhere, including France⁴⁵ and the United Kingdom.⁴⁶ In the United Kingdom, the national NBS program uses a safety net for infants with a VHIRT value but no mutations identified on a limited mutation panel. The United Kingdom approach is to undertake a repeat IRT measurement on a sample obtained on day 21 of life. If the IRT value remains elevated at this stage, the NBS is reported as positive, and the infant

referred for diagnostic assessment. This safety net approach has been useful for identifying infants with CF from a diverse ethnic population but at the expense of reducing positive predictive value. The adoption of various safety net algorithms is being considered by at least 9 Euro-

pean nations (Olaf Sommerburg, personal communication, October 2015).

Because of diverse political and demographic circumstances, there are at least 32 separate CF NBS programs in Europe, using a host of different screening algorithms.⁴⁷⁻⁵³ While still using IRT as the first tier of screening, some European programs have incorporated a second biomarker, pancreatitis-associated protein (PAP), into their CF NBS algorithms. Although issues have surfaced regarding PAP cut-off values,^{47,52,54} there are significant advantages of adding PAP analysis as a second tier of screening, including decreased recognition of carriers.^{55,56} However, using PAP analysis may also result in lower sensitivity. Methods to enhance sensitivity depend on the algorithm being used. While in France, Sarles et al⁵² decreased the PAP cut-off values recently to reach sufficient sensitivity, programs in Germany incorporated a failsafe strategy in which not only infants with high IRT and high PAP are referred for sweat testing, but also infants with low PAP values are referred for sweat testing if they display ultrahigh IRT levels (IRT/PAP-failsafe).⁴⁸ Pure biochemical IRT/PAP protocols nevertheless show a poor positive predictive value. More than two-thirds of all European CF screening programs use DNA, in accordance with the European CF Society recommendations,⁵⁷ Programs can still benefit from the use of PAP when combined with genetic analysis as a third tier as demonstrated by Vernooij-van Langen et al⁵¹ in 2012. Those protocols show not only sufficient sensitivity but also a positive predictive value comparable to that of IRT/DNA programs. Because of this experience, IRT/PAP/DNA protocols will be implemented as a

national screening program from 2016 and 2017 in Germany and in France, respectively. In a post hoc analysis, the effect of an ultrahigh-IRT safety net was demonstrated for the German IRT/PAP/DNA CF NBS program (Olaf Sommerburg, personal communication, October 2015). In this NBS program, a high IRT leads to PAP analysis as the second-tier screen, and elevated PAP leads to the third-tier screen, that is, analysis for 31 CF-causing mutations. Data obtained from 372 906 neonates screened from 2008 to 2015 in southwest Germany were used to compare the potential impact of an ultrahigh IRT safety net that could trigger either sweat testing or DNA analysis in the absence of an elevated PAP level. If ultrahigh IRT triggered sweat testing, approximately 345 infants would undergo this diagnostic procedure. If ultrahigh IRT led instead to required DNA analysis, only 79 infants would subsequently undergo sweat testing. In either case, 71 infants with CF would be detected.

The diversity of CF NBS algorithms leads inevitably to a spectrum of risk for CF subsequent to a positive screen result. The likelihood of a “positive CF newborn screen” resulting in a diagnosis of CF can vary hugely, from close to 100% (as may occur if 2 CF-causing mutations are identified) to around 1% (as may occur in infants with positive NBS results because of VHIRT⁴²). Some infants present for follow-up without any supporting genetic information, whereas others may have had extensive genetic analysis performed. Regardless of the algorithm used, it must be emphasized that CF NBS is not a diagnostic test, and whether or not the baby has CF must be determined in follow-up care by diagnostic testing. As stated above, the essential component of this determination is the sweat test; the identification of a physiological abnormality not only supports the positive NBS result but may also help the family accept the diagnosis.⁵⁸ Clearly, the CF diagnosis is a serious one, and the sweat test provides an important safeguard to avoid mislabeling babies because of identity errors, or laboratory errors in IRT or DNA analysis.^{59,60} Furthermore, the sweat test will be performed on siblings,⁶¹ and comparison data can be invaluable. Even though there may appear to be less need of a sweat test in the presence of meconium ileus because meconium ileus provides obvious evidence of a physiological defect, a sweat test revealing elevated chloride should still be the criterion to confirm the diagnosis. There have been many instances where a neonatologist or surgeon did not properly inform the parents of an infant with meconium ileus about the high probability of CF, leading them to unrealistic expectations.

Thus, the next step in the follow-up of a positive NBS or prenatal test that suggests CF must be determination of the sweat chloride concentration. However, its interpretation and any additional tests needed to further explore the possibility of the CF diagnosis depend on the NBS algorithm used.

Confirming CF Diagnosis after Positive Newborn Screen without Detection of CF-Causing Mutations

Some positive results from a CF newborn screen do not include a DNA screen (for example, those using an IRT/IRT screen);

in this case, a sweat chloride test is directed, and the nature of the follow-up is determined by the chloride levels found (Table I, statements 6, 8, 10). If the sweat chloride level is ≥ 60 mmol/L, the infant has CF and *CFTR* genetic testing should be done (Table I, statement 7).

In most cases, if no CF-causing⁶ mutations are found in a CF NBS program that includes DNA analysis, the infant would be considered screen-negative. A safety net (such as very high or ultrahigh IRT), however, could be triggered to direct a sweat chloride test, with follow-up again determined by the chloride levels found (Table I, statements 6, 8, 10).

Confirming CF Diagnosis after Positive Newborn IRT/DNA Screen with Detection of 2 CF-Causing Mutations

Even with the identification of 2 CF-causing mutations (Table I, statement 11), the next step in a diagnostic work-up must be sweat chloride analysis (Table I, statement 12). Regardless of increased understanding of *CFTR* genetics, experts continue to emphasize the need for proof of *CFTR* dysfunction to complete the CF diagnosis.^{14,62} Some CF NBS programs demonstrate very high adherence; in France, for example, sweat test results are reported for up to 95.4% of infants with 2 CF-causing mutations (excluding those with meconium ileus),⁶³ but the same is not true for all CF NBS programs.⁵⁸ A review of diagnostic practices in the European Union showed that only 13 of 26 CF NBS programs reported routinely including sweat testing for infants with 2 CF-causing mutations.⁵⁸ Four programs never conducted sweat testing in these infants, whereas it was sometimes conducted in 6 other programs. Analysis of data in the US CF Foundation Patient Registry (CFFPR) suggests a similar lack of adherence to this guideline: nearly 24% of US patients with 2 CF-causing mutations do not have associated sweat chloride results.¹¹ Although the policy of a CF NBS program may be to recommend sweat chloride confirmation, the responsibility for performing the test resides with the primary care provider and the CF clinician assuming care. If the decision is made by the diagnostician to assign a diagnosis of CF without sweat chloride testing, the CF NBS program is left without these data, as are the CF patient registries.

Improving adherence may require a better understanding of the potential challenges in sweat testing young infants and improved performance of sweat test procedures: (1) the

sweat test itself remains challenging because of higher rates of insufficient sweat (quantity not sufficient) in neonates;

(2) the diagnosis of CF already seems confirmed to some parents when they arrive with the baby at a CF center; (3) the presence of intermediate sweat chloride levels in babies with 2 CF-causing mutations can cause confusion in the family and primary care providers; (4) it may be difficult to order a sweat test if it has been postponed and a CF diagnosis has been presumptively made and recorded in a medical chart; (5) sweat test results do not impact follow-up modalities in these infants; (6) sweat test results, unlike genetic

analysis, do not provide utility for personalized medicine;

(7) because of the high costs of analytic devices, sweat chloride testing often is not performed in countries that have limited resources or consider CF rare; and (8) reimbursement for sweat testing may be problematic; in many areas of the world, including some of the US, the sweat test is not part of NBS funding, and health insurance companies may not pay for the test, and certainly not for a repeat sweat test, if they believe it is unnecessary.

Despite these issues, it is clear that sweat tests can be performed successfully in most infants during the first month of life.^{44,64} Rock and Farrell⁶⁴ reported that patients diagnosed in Wisconsin following positive CF NBS from 2004 to 2014 had sweat testing performed at a mean age of 21 days (SD of 16 days) and a median age of 16 days. There were 2 infants whose sweat testing was delayed, which skewed the data distribution (an infant who had meconium ileus with surgery and prolonged hospitalization, with sweat test at 55 days of age, and an infant born prematurely at 34 weeks' gestation, who was identified as a homozygous c.1521_1523delCTT [legacy: F508del] patient with birth weight of 2126 g and whose sweat test was delayed until 100 days of age to ensure a sufficient quantity of sweat). This study used the Gibson-Cooke method. Other data show similar, if not better results regarding adequate sweat quantity with the Macroduct collector (Wescor Inc, Logan, Utah).⁶⁵

It is important to explore ways to improve adherence. Requiring sweat test results for entry into the European and US CF Foundation data registries might emphasize the need for the information for diagnosis. Thus, beginning in 2017, the CF Foundation will require that a sweat chloride value be entered for enrollment of a newly diagnosed patients in the CF registry.

In addition to the sweat test, *CFTR* gene analysis on DNA obtained directly from the infant should ideally be performed as part of the diagnostic evaluation, even if a genotype was reported as part of the newborn screen (Table I, statement 2). This recommendation is new but is appropriate in the expanding era of *CFTR* modulator therapy in which the genotype must be known unequivocally. Although this group of infants has 2 reported CF-causing mutations, some *CFTR* mutations (such as c.3717 + 12191 C→T [legacy: 3849 + 10kB C→T] and c.3454G>C [legacy: D1152H]) are known to result in an increased probability of a sweat chloride level well below 60 mmol/L, even into the "normal" range, in individuals with CF.⁶⁶⁻⁷⁰ In the case of certain other mutations, a more in-depth

genetic analysis may be useful. For example, if the c.350G>A mutation (legacy: R117H) is identified, exploration of the polyT status and possibly TG repeats is essential because of their effects on both function and penetrance.⁷¹⁻⁷³ Such in-depth genetic analysis is not always done as part of the diagnostic evaluation following CF NBS. However, because the polyT tract is highly significant in individuals with R117H, it should be added to the diagnostic evaluation to better identify, early on, infants with CF vs those who should be categorized as CRMS/CF screen positive, inconclusive diagnosis (CFSPID), with a risk of converting

to a CF diagnosis⁷⁴ (**Appendix**, case study 1; available at www.jpeds.com). There are also uncommon instances of 2 CF-causing mutations occurring in cis^{60,75}; in this scenario, the sweat test would be normal and additional genetic analysis including parental testing could explain the result and prevent medicalization of this healthy infant.

Confirming CF Diagnosis after Positive Newborn Screen with Detection of 1 CF-Causing Mutation

Not all infants with CF will have 2 CF-causing mutations detected (**Table I**, statement 13). Because of the lack of clarity on the disease liability of various *CFTR* mutations, the sweat test is an especially crucial part of the diagnostic algorithm for this group of infants (**Table I**, statements 10, 15), but interpretations can be difficult. The mutation effects are not always clear-cut because of the presence of modifier genes, or environmental or epigenetic influences: the same mutations may be associated with CF in some patients, but with CRMS/CFSPID in others.¹⁸

In general, in this group of infants, a sweat chloride level ≥ 60 mmol/L is clearly indicative of CF (**Table I**, statement 15) and a sweat chloride level < 30 mmol/L indicates CF is unlikely (**Table I**, statement 8). A sweat chloride level of 30–59 mmol/L, however, should lead to a second sweat test (**Table I**, statement 19). Often, this second sweat test will produce resolution of the intermediate screening test result, with a decrease to < 30 mmol/L resulting in discharge from the program as healthy, or an increase to ≥ 60 mmol/L as diagnostic of CF. However, in some instances the sweat chloride levels remain intermediate and inconclusive. In this scenario (1 detected CF-causing mutation), extended genotyping, clinical evaluation by a CF specialist by 2 months of age, and another sweat chloride test repeated by 6 months of age are recommended to seek resolution.^{18,19} Asymptomatic infants who continue to display intermediate sweat chloride levels (30–59 mmol/L) and whose genetic analysis does not provide clarity (< 2 CF-causing mutations) should be categorized as CRMS/CFSPID and followed at a CF care center (**Table I**, statements 18 and 20). (More details on frequency of CRMS/CFSPID, appropriate diagnostic evaluation, and outcomes can be found in the report by Ren et al.⁷⁴) Some CF NBS programs may

use nasal potential difference (NPD) or other tests to clarify CFTR physiological dysfunction, particularly if insufficient sweat can be collected for analysis.

Although it is appropriate from the perspective of both physician and patient to label newborns who screen positive with intermediate sweat chloride values and < 2 CF-causing mutations as CRMS/CFSPID, when patients display a clear history of CF-like lung disease plus intermediate sweat chloride and abnormal NPD/intestinal current measurement (ICM), they need CF management and must be diagnosed with CF.

Infants whose newborn screen has identified 2 *CFTR* mutations with ≤ 1 known to be CF-causing and who display

normal sweat chloride levels should also be categorized as CRMS/CFSPID and followed (Table I, statement 18).

Infants who are screen positive with 1 CF-causing mutation but who produce insufficient sweat for analysis should be retested as described in Farrell et al²⁹ (Appendix, case study 2).

Additional Tests

A small percentage of infants who are eventually diagnosed with CF do not meet definitive CF diagnostic criteria at the time of their first evaluation following a positive CF NBS result. Typically, in this group, sweat chloride levels do not provide the information needed to properly identify CF. Extended genotype (or any genotype) results may not be available initially, and even with the substantial progress of the past decade, will not be able to resolve all cases because of extremely rare alleles with insufficient clinical data or partially penetrant alleles with variable clinical consequences that cannot be predicted. Thus, we must turn to other possible biomarkers to provide an understanding of the level of CF risk for these families as well as appropriate care for the patients. Embracing a wide array of biomarkers may help clinicians face the challenge of defining the risk of CF for children with inconclusive genetic data. Gathering information about these biomarkers in early childhood would help evaluate the penetrance of *CFTR* variants and describe the full spectrum of disorders associated with *CFTR* mutations, extending our knowledge about how *CFTR* variants (and other genes) contribute to disease beyond our current understanding of CF.

Fecal Elastase (FE)

Demonstration of low FE levels <200 mg/g (in the absence of diarrhea) has been proposed as an indicator of pancreatic insufficiency and a diagnostic marker for CF. FE values fluctuate through the first 12 months of life. In a study⁷⁶ of 61 infants diagnosed with CF through NBS, 48 infants (79%) had initial FE <200 mg/g; 13 of these 48 infants (27%) had at least 1 FE value >200 mg/g over the next several months before resolving into levels <200 mg/g, and 4 of 48 infants (8%), on the other hand, displayed pancreatic-sufficient levels >200 mg/g by >9 months of age. In addition, 13 infants (21%) had initial FE >200 mg/g; 10 of these (77%) had pancreatic sufficiency at the end of the first year of life.

FE may be useful as an interim measure in those

infants with pancreatic insufficiency who have "quantity not sufficient" sweat test results, permitting appropriate treatment until repeat sweat testing is successful. This strategy has been used in Switzerland.⁷⁷ However, despite the early enthusiasm for this biomarker,^{78,79} FE is of limited value in diagnosing CF definitively, as many individuals with CF retain normal levels of FE.^{76,80} It also has been disappointing when used to try to determine which infants, categorized as CFSPID from a newborn screen, will eventually be diagnosed with CF.⁸¹ When FE levels were measured over the first 24 months of life in a cohort of 36 infants with CFSPID, all but one remained >200 mg/g, and none of

the babies later diagnosed with CF displayed low FE levels, remaining pancreatic sufficient (Tanja Gonska, personal communication, October 2015).

Trypsinogen

Trypsinogen levels are already used to identify infants at high risk for CF and may be used to better advantage. Serum trypsinogen levels were serially examined over the first 36 months of life in 82 infants categorized as CFSPID and 80 infants diagnosed with CF.⁸¹ Overall, infants with CFSPID had significantly lower NBS IRT than did infants with CF. Furthermore, nine of the 82 (11%) infants with CFSPID were subsequently diagnosed with CF, and these patients had significantly higher serial serum trypsinogen levels than did those infants who remained in the group with CFSPID. Thus, serial trypsinogen levels may contribute useful information.

NPD and ICM

As in the 1996-1998 and 2007-2008 CF Foundation consensus development processes, the overwhelming importance of demonstrating CFTR dysfunction to confirm a CF diagnosis, combined with the limitations of sweat tests, creates great appeal for other CFTR functional assays. This is especially true for those assays providing added value from an *in vivo* strategy and a drug responsiveness component that increases sensitivity.

Measurements of CFTR (and the epithelial sodium channel) activity in nasal epithelium readily distinguish the healthy young infant from one with CF. In fact, NPD, when attempted in babies with intermediate sweat chloride levels by very experienced, skilled operators, can provide reliable results. In 1 study of 11 children (aged 3.5 ± 1.5 years) with nondiagnostic sweat chloride values, NPD testing was able to demonstrate normal CFTR function in 7 of the children; only 1 showed NPD indicative of pathology (the test could not be completed in 3 children because of poor cooperation) (Michael Wilschanski, personal communication, October 2015). Another study of NPD conducted in 23 young children (aged 3 months to 4 years) with high IRT values, 1 CF-causing mutation identified and intermediate sweat chloride levels demonstrated a connection between NPD results and clinical outcome.⁸² Although NPD results were not interpretable in 2 of the children, 13 of the 21 remaining children (62%) had NPD scores in the CF range; 2 *CFTR* mutations were subsequently found in all 13 patients, and 9 of the 13 had developed chronic lung disease at follow-up. Of

the 8 children (38%) with normal NPD scores, only 2 children had 2 *CFTR* mutations (both of which are associated with a wide spectrum of phenotypes), and none had developed a CF-like lung disease at follow-up. Repeated sweat test results were obtained in 5 of these 8 children; all had sweat chloride values <60 mmol/L. A CF diagnosis was ruled out in 6 of the 8 children.

However, NPD is not possible or reliable in every situation, and analysis of CFTR function in the intestine (ICM) may be considered, aided by the fact that CFTR is highly expressed in intestinal epithelia, offering high specificity and sensitivity for the test.^{83,84} Like NPD, ICM measurements must be

conducted in specific high quality reference centers with experienced, very skilled personnel.^{85,86} ICM can be used to confirm a diagnosis of CF in the context of intermediate sweat chloride levels.^{87,88} Ion transport in the intestine is a very sensitive measure of CFTR function: only 10% of wild-type CFTR is necessary to prevent intestinal pathology in CF, and a very small gain in CFTR expression (from 1% to 5% of wild-type) results in large gains in chloride secretion (from 5% to 25% of wild-type levels).⁸³ Because of this sensitivity, ICM can be used to better characterize variants of unknown disease liability.

Combining results from ICM and NPD, when available, can provide an even clearer picture of the spectrum of CFTR function, from CF-causing to healthy levels (Isabelle Sermet-Gaudelus, personal communication, October 2015). If the ICM is normal, other pathologies, such as immunodysregulation polyendocrinopathy enteropathy X-linked syndrome, should be considered.

NPD and ICM have the potential to be useful as surrogate outcomes because they are in vivo/ex vivo measurements and may play a useful supplementary role for the diagnosis of CF (Table I, statement 15). However, they are not sufficiently validated at present to recommend routine use and are not available on a wide scale because of the expertise and experience required to obtain reliable measurements (Table I, statement 14). Nevertheless, these are increasingly attractive, advanced research methods that will help us better understand the nature of the spectrum of CF disease and CRMS/CFSPID. And, with more routine use in European CF centers, greater application will undoubtedly occur.

Despite these advances, some infants still provide a diagnostic challenge. Thus, long-term follow-up evaluations of children with various levels of CFTR function are needed to determine the best approach for diagnosis and management of children without the signs and symptoms of established, unequivocal CF. The best approach may involve sensitive functional tests such as NPD and ICM tests in combination with genotype-phenotype studies (such as correlation with the CFTR2 database⁶) and data collected from CF registries.

Clinical/Respiratory Evaluations in Uncertain Cases

Clinical evaluations for respiratory pathology are of little value

in cases of uncertain CF during infancy. Signs and symptoms are unlikely and nonspecific, although

chronic cough should raise suspicion. An infant pulmonary function test (PFT) that demonstrates gas trapping or reduced forced expiratory flows could be of value, but the measurement is not standardized, the capability of performing an infant PFT is not widely available, and other obstructive lung problems (such as wheezing) can produce similar PFT results.⁸⁹ Lung clearance index using the SF₆ method for infants is sensitive, but again, not widely available (N₂ washout is not currently developed for infants).⁹⁰⁻⁹² Chest radiographs are worthwhile, but the changes are often subtle and nonspecific. Chest computed tomography scans performed in infants diagnosed with CF following NBS through the Australian Respiratory Early Surveillance Team for CF in-

tensive surveillance program revealed 29.3% with bronchiectasis by 3 months of age,⁹³ although findings differed in a United Kingdom cohort.⁹⁴ This finding is in keeping with earlier observations from autopsy-based studies.⁹⁵ However, a study of chest computed tomography in asymptomatic infants with CF suggested that this imaging is usually not warranted because the changes during infancy are typically very mild.⁹⁴ Thus, in uncertain cases, the radiation burden and risks of anesthesia are unlikely to be balanced by benefit.

Induced sputum or bronchoalveolar lavage performed in children with CF aged 3 to 7 years may reveal evidence of bacteria common in CF, including *Pseudomonas aeruginosa*, *Stenotrophomonas maltophilia*, and *Staphylococcus aureus*.⁹⁶ To understand the significance of culturing CF-typical bacteria in this population, respiratory samples collected over the first 2 years of life in children with either CF (n = 23) or non-CF chronic suppurative lung disease (n = 124) were compared by retrospective analysis (Hannah Blau, personal communication, October 2015). At the time of the first culture, there was no significant difference between the bacterial species cultured from children with CF compared with those cultured from children with other lung diseases. However, when all sputum culture results from the first 2 years were analyzed, cultures from children with CF were significantly more likely to contain *P aeruginosa*, *Enterobacter* species, *Escherichia coli*, *Klebsiella oxytoca*, and *Serratia* species than were control cultures. *P aeruginosa*-positive cultures were found in 32/124 (about 26%) of the children with non-CF lung disease compared with 17/23 (74%) children with CF, although chronic *P aeruginosa* infection was rare in either case. The conclusion from this retrospective analysis is that cultures from induced sputum may provide a useful disease marker in the infant with suspected CF.

by the specialist CF team by 35 days of age and no later than day 58,⁶² whereas the recommended US standard of care specifies diagnosis by 2-4 weeks without specifying care at a CF center.⁹ Therefore, to ensure timeliness, follow-up evaluations needed to decide CF status should be completed within 2-4 weeks of age when infants are hopefully still in a preclinical stage. Even by 2 weeks, however, malnutrition may be present,^{97,98} and there is a risk of potentially fatal electrolyte depletion and hyponatremic dehydration⁹⁹ (**Appendix**, case study 3). Hence, it is important in some circumstances to make a presumptive diagnosis of CF to enable

Consensus Statements on Diagnosing CF in Screened Populations

Taking into account the available evidence, the 2015 CF Foundation Consensus Committee agreed upon the statements shown in **Table I** for diagnosing screened populations. Sweat tests, *CFTR* mutation analysis, and the ancillary tests described above may all prove valuable for establishing or confirming a CF diagnosis in children with positive prenatal testing or neonatal screening. The European CF Society Standards of Care state that the majority of infants with a confirmed diagnosis after NBS should be seen

appropriate treatment and follow-up while pursuing diagnostic confirmation (Table I, statement 4).

Once a diagnosis is established, genetic counseling should be offered to families of all infants with CF or CRMS/CFSPID.^{18,19,57,100} In other words, all families of CF NBS positive newborns should receive genetic counseling, whether the infant turns out to be a carrier or is truly affected. Recommendations have been published on methods of genetic counseling.^{101,102}

Enrollment into the US CF Foundation Patient Registry

The US CF Foundation Patient Registry was created in 1966 to collect data on health outcomes, clinical care and demographic characteristics of people with CF who receive care at CF Foundation-accredited care centers.¹⁰³ Clear, reliable data must be entered into the CFFPR and other registries to permit quality analysis of CF NBS programs and clinical outcomes of all those with CF. Entering diagnostic information under consistent guidelines is critically important for all patients diagnosed with the disease, including those diagnosed immediately following a positive newborn screen, as well as those diagnosed at a later age, such as those with a false-negative newborn screen, or those who had a positive newborn screen and a negative initial sweat test. It is important to accurately record dates, test results, and treatment from the initial contact. Because CFFPR consent often is not obtained until the patient has been seen at the CF center for 1 or more visits, it is essential to ask families for consent as soon as possible to allow retrospective data (ie, before consent) to be entered in the registry, subject to institutional review board approval. Appropriate guidelines for data entry on consented patients diagnosed following prenatal screening or NBS are presented below.

Guidelines for Date of Confirmation of CF Diagnosis following Prenatal Testing

Prenatal testing showing 2 CF-causing *CFTR* mutations (in *trans*, as confirmed by parental testing) is generally adequate for a presumptive diagnosis of CF. In most cases, prenatal testing is done when both parents are known carriers either because of population screening with cascade testing or as a result of testing because of

a positive family history. However, because of varying prenatal testing and reporting protocols, infants with prenatal diagnosis should have the date of diagnosis listed as the date of birth (ie, diagnosed at 1 day of age). In addition, infants with positive prenatal testing results should always have a sweat test performed for confirmation of the diagnosis.

Guidelines for Date of Presumptive Diagnosis in CF NBS

It is important to provide a date of presumptive diagnosis for the purpose of evaluating timeliness of diagnosis and treatment by CF centers in conjunction with NBS programs.

An infant can be presumed to have CF in any of the following clinical circumstances: (1) positive CF NBS test result reveals 2 CF-causing *CFTR* mutations; (2) CF NBS test is positive based on a specific state's algorithm, and there are clinical features consistent with CF, such as growth failure or malabsorption; or (3) infant has meconium ileus, with or without a positive CF NBS test.

In each of these cases, confirmation of diagnosis should proceed as quickly as possible, but treatment should not be delayed while awaiting diagnostic confirmation.

Guidelines for Date of Confirmation of CF Diagnosis Subsequent to NBS

A sweat test should be performed in all cases of presumptive

diagnosis, as soon as possible. It may be delayed because of illness, prematurity, or, rarely, other circumstances (eg, geographic or weather-related) but should not otherwise be delayed. A CF diagnosis is considered confirmed only if: (1) sweat chloride is ≥ 60 mmol/L; (2) CF-causing *CFTR* mutations are identified and the sweat chloride value is ≥ 30 mmol/L; (3) 2 variable or uncharacterized *CFTR* mutations are identified and physiological testing such as NPD or ICM reveal *CFTR* dysfunction, and the sweat chloride value is

≥ 30 mmol/L; (4) 2 CF-causing *CFTR* mutations are identified from a blood specimen obtained directly from the affected infant during follow-up—a genotype report from the NBS program is not sufficient because of the risk of errors (parental testing may be required in some circumstances to verify that 2 mutations are in *trans*,⁶⁰ in cases where genotype and *CFTR* functional testing results are at variance [eg, normal sweat value and 2 *CFTR* mutations are present]); or (5) NPD or ICM values typical of CF are present (CF-typical values must be defined by an experienced center performing the test).

Guidelines for Date of Confirmation of CF Diagnosis Because of “Diagnostic Drift” or Because of Genetic Reclassification

A change to a CF diagnosis most often occurs when an infant

initially categorized as CRMS/CFSPID develops clinical signs or symptoms of CF. In these cases, the CFFPR entry should note the date of clinical diagnosis of CF, as well as the date of the onset of clinical or laboratory findings that led to the change in diagnostic category (such as an increase in sweat chloride into the diagnostic range, or infection with *P aeruginosa*).

Rarely, children may move from the

CRMS/CFSPID category to a CF diagnosis because of a new recognition of the pathologic consequences of their *CFTR* alleles. In these cases, the CFFPR entry should be updated to the date for reclassification of their genotype.

The guidelines described above should enhance the quality of data in the CFFPR. Other CF registries may wish to consider these recommendations. It would be ideal to have international harmony and consistency in the global CF registries. Perhaps the proper use of *International Statistical Classification of Diseases and Related Health Problems, 10th Revision* codes on an international scale, reflects a clear application of

Table II. Educational resources for diagnosis of CF

Sources	Content
www.cff.org	<ul style="list-style-type: none"> • clinical and research information for CF clinicians and primary caregivers • educational information for families regarding NBS, clinical care, and resources • CF community blog for people living with CF, their families, their friends, and their care team • links to NBS quality improvement videos • link to NBS video for families
http://www.nemours.org/service/medical/cvsticfibrosis.html	<ul style="list-style-type: none"> • NBS video for primary care providers and other professional caregivers

diagnostic categories created by consensus, would contribute to harmony.

Educational Resources

The diagnosis of CF has become increasingly complex, as *CFTR* mutations resulting in a wide spectrum of dysfunction have been increasingly identified. To address this challenge and help educate CF centers and care providers in CF diagnosis, efforts will be put in place to facilitate implementation. Additional educational resources are also available ([Table II](#)).

Conclusions

Prompt diagnosis of CF is vital for optimizing outcomes. The widespread use of CF NBS has enabled the diagnosis of CF in most affected infants before obvious clinical signs, but diagnosis can be difficult. To take advantage of burgeoning knowledge of the impact of various *CFTR* mutations and recent studies on cohorts with unclear CF diagnoses, the CF Foundation convened a committee of experts from around the world to update consensus guidelines on diagnosis of CF with an emphasis on screened populations. The committee concluded that all diagnoses should be established by demonstrating *CFTR* dysfunction—by sweat chloride test where possible, or potentially by other methods such as NPD or ICM where necessary. Even in babies with 2 CF-causing mutations detected by NBS, diagnosis must be confirmed by demonstrating *CFTR* dysfunction. Guidelines for making a presumptive diagnosis were also developed. Following the

opinions and advisory boards. J.D. receives funding from Vertex, Proteostasis, Pulmocide, Actavis, PTC, and Enterprise Therapeutics. D.S. receives grants from the CF Foundation. M.W. receives funding from Advisory Board of PTC Therapeutics, Inc. S.G. serves on advisory boards of Vertex Pharmaceuticals, Inc and Gilead Sciences, Inc. S.M. has served as a consultant for Vertex Pharmaceuticals, Inc. The other authors declare no conflicts of interest, real or perceived.

References

recommendations for screened populations should provide clarity to CF care providers and families, and ensure treatment is provided when needed, while avoiding medicalization of healthy infants. ■

Author Disclosures

PF. receives honoraria from the CF Foundation as National Facilitator for NBS Quality Improvement. T.W. is an employee of the CF Foundation. A.M. reports financial relationships with Vertex, Novartis, and Aptalis for expert

1.

- Kosorok MR, Wei WH, Farrell PM. The incidence of cystic fibrosis. *Stat Med* 1996;15:449-62.
2. Palomaki GE, FitzSimmons SC, Haddow JE. Clinical sensitivity of pre- natal screening for cystic fibrosis via CFTR carrier testing in a United States panethnic population. *Genet Med* 2004;6:405-14.
 3. Hamosh A, FitzSimmons SC, Macek M, Knowles MR, Rosenstein BJ, Cutting GR. Comparison of the clinical manifestations of cystic fibrosis in black and white patients. *J Pediatr* 1998;132:255-9.
 4. Kerem B, Rommens JM, Buchanan JA, Markiewicz D, Cox TK, Chakravarti A, et al. Identification of the cystic fibrosis gene: genetic analysis. *Science* 1989;245:1073-80.
 5. Dorfman R, for the CFMD/CFTR1 Team. Cystic Fibrosis mutation database [Internet]. <http://www.genet.sickkids.on.ca/cftr/app>. Updated April 2011. Accessed May 3, 2016.
 6. CFTR2@Johns Hopkins—home page [Internet]. <http://cftr2.org/>. Updated August 2016. Accessed October 21, 2016.
 7. Grosse SD, Boyle CA, Botkin JR, Comeau AM, Kharrazi M, Rosenfeld M, et al. Newborn screening for cystic fibrosis: evaluation of benefits and risks and recommendations for state newborn screening programs. *MMWR Recomm Rep* 2004;53(RR-13):1-36.
 8. Campbell PW 3rd, White TB. Newborn screening for cystic fibrosis: an opportunity to improve care and outcomes. *J Pediatr* 2005;147(Suppl 3):S2-5.
 9. Farrell PM, Rosenstein BJ, White TB, Accurso FJ, Castellani C, Cutting GR, et al. Guidelines for diagnosis of cystic fibrosis in newborns through older adults: Cystic Fibrosis Foundation consensus report. *J Pediatr* 2008;153:S4-14.
 10. De Boeck K, Wilschanski M, Castellani C, Taylor C, Cuppens H, Dodge J, et al. Cystic fibrosis: terminology and diagnostic algorithms. *Thorax* 2006;61:627-35.
 11. Ren CL, Fink AK, Petren K, Borowitz DS, McColley SA, Sanders DB, et al. Outcomes of infants with indeterminate diagnosis detected by cystic fibrosis newborn screening. *Pediatrics* 2015;135:e1386-92.
 12. Parad RB, Comeau AM. Diagnostic dilemmas resulting from the immunoreactive trypsinogen/DNA cystic fibrosis newborn screening algorithm. *J Pediatr* 2005;147(Suppl 3):S78-82.
 13. Kharrazi M, Yang J, Bishop T, Lessing S, Young S, Graham S, et al. Newborn screening for cystic fibrosis in California. *Pediatrics* 2015;136:1062-72.
 14. Levy H, Farrell PM. New challenges in the diagnosis and management of cystic fibrosis. *J Pediatr* 2015;166:1337-41.
 15. Tluczek A, Chevalier McKechnie A, Lynam PA. When the cystic fibrosis label does not fit: a modified uncertainty theory. *Qual Health Res* 2010;20:209-23.
 16. Tluczek A, Orland KM, Cavanagh L. Psychosocial consequences of false-positive newborn screens for cystic fibrosis. *Qual Health Res* 2011;21:174-86.
 17. Nelson MR, Adamski CR, Tluczek A. Clinical practices for intermediate sweat tests following abnormal cystic fibrosis newborn screens. *J Cyst Fibros* 2011;10:460-5.
 18. Munck A, Mayell SJ, Winters V, Shawcross A, Derichs N, Parad R, et al. Cystic Fibrosis Screen Positive, Inconclusive Diagnosis (CFSPID): a new designation and management recommendations for infants with an inconclusive diagnosis following newborn screening. *J Cyst Fibros* 2015;14:706-13.

19. Cystic Fibrosis Foundation, Borowitz D, Parad RB, Sharp JK, Sبادosa KA, Robinson KA, et al. Cystic Fibrosis Foundation practice guidelines for the management of infants with cystic fibrosis transmembrane conductance regulator-related metabolic syndrome during the first two years of life and beyond. *J Pediatr* 2009;155(Suppl 6):S106-16.
20. Ooi CY, Dupuis A, Ellis L, Jarvi K, Martin S, Gonska T, et al. Comparing the American and European diagnostic guidelines for cystic fibrosis: same disease, different language? *Thorax* 2012;67:618-24.
21. Cystic Fibrosis Foundation. Cystic Fibrosis Foundation Patient Registry 2014 annual data report. Bethesda (MD): Cystic Fibrosis Foundation; 2015.
22. Elborn JS. Cystic fibrosis. *Lancet* 2016;doi:10.1016/S0140-6736(16)00576-6.
23. Elborn JS, Bell SC, Madge SL, Burgel P-R, Castellani C, Conway S, et al. Report of the European Respiratory Society/European Cystic Fibrosis Society task force on the care of adults with cystic fibrosis. *Eur Respir J* 2016;47:420-8.
24. Cystic Fibrosis Canada. The Canadian Cystic Fibrosis Registry. 2014 annual report. [Internet]. <https://cysticfibrosis.uberflip.com/i/705240-cystic-fibrosis-canada-registry>. Accessed October 22, 2016.
25. Bell SC, De Boeck K, Amaral MD. New pharmacological approaches for cystic fibrosis: promises, progress, pitfalls. *Pharmacol Ther* 2015;145:19-34.
26. Farrell PM, Lai HJ, Li Z, Kosorok MR, Laxova A, Green CG, et al. Evidence on improved outcomes with early diagnosis of cystic fibrosis through neonatal screening: enough is enough! *J Pediatr* 2005;147(Suppl 3):S30-6.
27. Dijk FN, Fitzgerald DA. The impact of newborn screening and earlier intervention on the clinical course of cystic fibrosis. *Paediatr Respir Rev* 2012;13:220-5.
28. Salinas D, Azen C, Young S, Keens T, Kharrazi M, Parad R. Phenotypes of California CF newborn screen-positive children with CFTR 5T allele by TG repeat length. *Genet Test Mol Biomarkers* 2016;20:496-503.
29. Farrell PM, White TB, Ren CL, Hempstead SE, Accurso F, Derichs N, et al. Diagnosis of cystic fibrosis: consensus guidelines from the Cystic Fibrosis Foundation. *J Pediatr* 2017;181S:S4-15.
30. Baker MW, Groose M, Hoffman G, Rock M, Levy H, Farrell PM. Optimal DNA tier for the IRT/DNA algorithm determined by CFTR mutation results over 14 years of newborn screening. *J Cyst Fibros* 2011;10:278-81.
31. Kloosterboer M, Hoffman G, Rock M, Gershan W, Laxova A, Li Z, et al. Clarification of laboratory and clinical variables that influence cystic fibrosis newborn screening with initial analysis of immunoreactive trypsinogen. *Pediatrics* 2009;123:e338-46.
32. Sanders DB, Lai HJ, Rock MJ, Farrell PM. Comparing age of cystic fibrosis diagnosis and treatment initiation after newborn screening with two common strategies. *J Cyst Fibros* 2012;11:150-3.
33. Padoan R, Genoni S, Moretti E, Seia M, Giunta A, Corbetta C. Genetic and clinical features of false-negative infants in a neonatal screening programme for cystic fibrosis. *Acta Paediatr* 2002;91:82-7.
34. Sontag MK, Lee R, Wright D, Freedenberg D, Sagel SD. Improving the sensitivity and positive predictive value in a cystic fibrosis newborn screening program using a repeat immunoreactive trypsinogen and genetic analysis. *J Pediatr* 2016;175:150-8.
35. Rock MJ, Mischler EH, Farrell PM, Bruns WT, Hassemer DJ, Laessig RH. Immunoreactive trypsinogen screening for cystic fibrosis: characterization of infants with a false-positive screening test. *Pediatr Pulmonol* 1989;6:42-8.
36. Clinical and Laboratory Standards Institute. Newborn screening for cystic fibrosis; approved guideline. CLSI document NBS05-A. Wayne (PA): Clinical and Laboratory Standards Institute; 2011.
37. Prach L, Koepke R, Kharrazi M, Keiles S, Salinas DB, Reyes MC, et al. Novel CFTR variants identified during the first 3 years of cystic fibrosis newborn screening in California. *J Mol Diagn* 2013;15:710-22.
38. Kammesheidt A, Kharrazi M, Graham S, Young S, Pearl M, Dunlop C, et al. Comprehensive genetic analysis of the cystic fibrosis transmem-

- brane conductance regulator from dried blood specimens—implications for newborn screening. *Genet Med* 2006;8:557-62.
39. Hughes EE, Stevens CF, Saavedra-Matiz CA, Tavakoli NP, Krein LM, Parker A, et al. Clinical sensitivity of cystic fibrosis mutation panels in a diverse population. *Hum Mutat* 2016;37:201-8.
 40. Sosnay PR, Salinas DB, White TB, Ren CL, Farrell PM, Raraigh KS, et al. Applying cystic fibrosis transmembrane conductance regulator genetics and CFTR2 data to facilitate diagnoses. *J Pediatr* 2017;181S:S27-32.
 41. Pique L, Graham S, Pearl M, Kharrazi M, Schrijver I. Cystic fibrosis newborn screening programs: implications of the CFTR variant spectrum in nonwhite patients. *Genet Med* 2016;doi:10.1038/gim.2016.48. [Epub ahead of print].
 42. Kay DM, Langfelder-Schwind E, DeCelle-Germana J, Sharp JK, Maloney B, Tavakoli NP, et al. Utility of a very high IRT/No mutation referral category in cystic fibrosis newborn screening. *Pediatr Pulmonol* 2015;50:771-80.
 43. Sontag MK, Wright D, Beebe J, Accurso FJ, Sagel SD. A new cystic fibrosis newborn screening algorithm: IRT/IRT1 upward arrow/DNA. *J Pediatr* 2009;155:618-22.
 44. Comeau AM, Parad RB, Dorkin HL, Dovey M, Gerstle R, Haver K, et al. Population-based newborn screening for genetic disorders when multiple mutation DNA testing is incorporated: a cystic fibrosis newborn screening model demonstrating increased sensitivity but more carrier detections. *Pediatrics* 2004;113:1573-81.
 45. Munck A, Dhondt J-L, Sahler C, Roussey M. Implementation of the French nationwide cystic fibrosis newborn screening program. *J Pediatr* 2008;153:228-33, 233.e1.
 46. UK National Screening Committee [Internet]. https://www.gov.uk/government/uploads/system/uploads/attachment_data/file/281121/Cystic_Fibrosis_Lab_Guide_February_2014_v1.0_12_.pdf. Published February 2014. Accessed July 8, 2016.
 47. Sommerburg O, Hammermann J, Lindner M, Stahl M, Muckenthaler M, Kohlmüller D, et al. Five years of experience with biochemical cystic fibrosis newborn screening based on IRT/PAP in Germany. *Pediatr Pulmonol* 2015;50:655-64.
 48. Sommerburg O, Krulisova V, Hammermann J, Lindner M, Stahl M, Muckenthaler M, et al. Comparison of different IRT-PAP protocols to screen newborns for cystic fibrosis in three central European populations. *J Cyst Fibros* 2014;13:15-23.
 49. Torresani T, Fingerhut R, Rueegg CS, Gallati S, Kuehni CE, Baumgartner MR, et al. Newborn screening for cystic fibrosis in Switzerland—consequences after analysis of a 4 months pilot study. *J Cyst Fibros* 2013;12:667-74.
 50. Krulišová V, Balašáková M, Skalická V, Piskáčková T, Holubová A, Padeřová J, et al. Prospective and parallel assessments of cystic fibrosis newborn screening protocols in the Czech Republic: IRT/DNA/IRT versus IRT/PAP and IRT/PAP/DNA. *Eur J Pediatr* 2012;171:1223-9.
 51. Vernooij-van Langen AMM, Loeber JG, Elvers B, Triepels RH, Gille JJP, Van der Ploeg CPB, et al. Novel strategies in newborn screening for cystic fibrosis: a prospective controlled study. *Thorax* 2012;67:289-95.
 52. Sarles J, Giorgi R, Berthéze P, Munck A, Cheillan D, Dagorn J-C, et al. Neonatal screening for cystic fibrosis: comparing the performances of IRT/DNA and IRT/PAP. *J Cyst Fibros* 2014;13:384-90.
 53. Pybus S, Barben J, Castellani C, Dankert-Roelse J, Gartner S, Kashirskaya N, et al. Updated survey of newborn screening for cystic fibrosis [Abstract]. *J Cyst Fibros* 2014;13(Suppl 2):S48.
 54. Farrell PM, Sommerburg O. Toward quality improvement in cystic fibrosis newborn screening: progress and continuing challenges. *J Cyst Fibros* 2016;15:267-9.
 55. Seror V, Cao C, Roussey M, Giorgi R. PAP assays in newborn screening for cystic fibrosis: a population-based cost-effectiveness study. *J Med Screen* 2016;23:62-9.
 56. Sarles J, Berthéze P, Le Louarn C, Somma C, Perini J-M, Catheline M, et al. Combining immunoreactive trypsinogen and pancreatitis-associated protein assays, a method of newborn screening for cystic fibrosis that avoids DNA analysis. *J Pediatr* 2005;147:302-5.

57. Castellani C, Southern KW, Brownlee K, Dankert Roelse J, Duff A, Farrell M, et al. European best practice guidelines for cystic fibrosis neonatal screening. *J Cyst Fibros* 2009;8:153-73.
58. Southern KW, Munck A, Pollitt R, Travert G, Zanolla L, Dankert- Roelse J, et al. A survey of newborn screening for cystic fibrosis in Europe. *J Cyst Fibros* 2007;6:57-65.
59. Rock MJ, Levy H, Zaleski C, Farrell PM. Factors accounting for a missed diagnosis of cystic fibrosis after newborn screening. *Pediatr Pulmonol* 2011;46:1166-74.
60. Bergougnoux A, Boureau-Wirth A, Rouzier C, Altieri J-P, Verneau F, Larrieu L, et al. A false positive newborn screening result due to a complex allele carrying two frequent CF-causing variants. *J Cyst Fibros* 2016;15:309-12.
61. Munck A, Houssin E, Roussey M. The importance of sweat testing for older siblings of patients with cystic fibrosis identified by newborn screening. *J Pediatr* 2009;155:928-30, e1.
62. Smyth AR, Bell SC, Bojcin S, Bryon M, Duff A, Flume P, et al. European Cystic Fibrosis Society standards of care: best practice guidelines. *J Cyst Fibros* 2014;13(Suppl 1):S23-42.
63. Munck A, Delmas D, Audrézet M-P, Lemonnier L, Cheillan D, Roussey M. The French CF newborn screening: optimization of the programme by a centralized tracking process [Abstract]. *J Cyst Fibros* 2016;15:S17.
64. Rock M, Farrell P. Sweat testing after abnormal CF newborn screening: a single center 20 year experience [Abstract]. *Pediatr Pulmonol* 2015;50(Suppl41):381.
65. Laguna TA, Lin N, Wang Q, Holme B, McNamara J, Regelman WE. Comparison of quantitative sweat chloride methods after positive newborn screen for cystic fibrosis. *Pediatr Pulmonol* 2012;47:736-42.
66. Highsmith WE, Burch LH, Zhou Z, Olsen JC, Boat TE, Spock A, et al. A novel mutation in the cystic fibrosis gene in patients with pulmonary disease but normal sweat chloride concentrations. *N Engl J Med* 1994;331:974-80.
67. Lebecque P, Leal T, De Boeck C, Jaspers M, Cuppens H, Cassiman J-J. Mutations of the cystic fibrosis gene and intermediate sweat chloride levels in children. *Am J Respir Crit Care Med* 2002;165:757-61.
68. Feldmann D, Couderc R, Audrezet M-P, Ferec C, Bienvenu T, Desgeorges M, et al. CFTR genotypes in patients with normal or borderline sweat chloride levels. *Hum Mutat* 2003;22:340.
69. Duguépéroux I, De Braekeleer M. The CFTR 3849+10kbC->T and 2789+5G->A alleles are associated with a mild CF phenotype. *Eur Respir J* 2005;25:468-73.
70. Sosnay PR, Siklosi KR, Van Goor F, Kaniecki K, Yu H, Sharma N, et al. Defining the disease liability of variants in the cystic fibrosis transmembrane conductance regulator gene. *Nat Genet* 2013;45:1160-7.
71. Kiesewetter S, Macek M, Davis C, Curristin SM, Chu CS, Graham C, et al. A mutation in CFTR produces different phenotypes depending on chromosomal background. *Nat Genet* 1993;5:274-8.
72. Thauvin-Robinet C, Munck A, Huet F, Génin E, Bellis G, Gautier E, et al. The very low penetrance of cystic fibrosis for the R117H mutation: a reappraisal for genetic counselling and newborn screening. *J Med Genet* 2009;46:752-8.
73. Groman JD, Hefferon TW, Casals T, Bassas L, Estivill X, Des Georges M, et al. Variation in a repeat sequence determines whether a common variant of the cystic fibrosis transmembrane conductance regulator gene is pathogenic or benign. *Am J Hum Genet* 2004;74:176-9.
74. Ren CL, Borowitz DS, Gonska T, Howenstine MS, Levy H, Massie J, et al. Cystic fibrosis transmembrane conductance regulator-related metabolic syndrome and cystic fibrosis screen positive, inconclusive diagnosis. *J Pediatr* 2017;181S:S45-51.
75. Cordovado SK, Hendrix M, Greene CN, Mochal S, Earley MC, Farrell PM, et al. CFTR mutation analysis and haplotype associations in CF patients. *Mol Genet Metab* 2012;105:249-54.
76. O' Sullivan BP, Baker D, Leung KG, Reed G, Baker SS, Borowitz D. Evolution of pancreatic function during the first year in infants with cystic fibrosis. *J Pediatr* 2013;162:808-12, e1.
- 77.

- Barben J, Rueegg CS, Jurca M, Spalinger J, Kuehni CE, Swiss Cystic Fibrosis Screening Group. Measurement of fecal elastase improves performance of newborn screening for cystic fibrosis. *J Cyst Fibros* 2016;15:313-7.
78. Beharry S, Ellis L, Corey M, Marcon M, Durie P. How useful is fecal pancreatic elastase 1 as a marker of exocrine pancreatic disease? *J Pediatr* 2002;141:84-90.
79. Borowitz D, Baker SS, Duffy L, Baker RD, Fitzpatrick L, Gyamfi J, et al. Use of fecal elastase-1 to classify pancreatic status in patients with cystic fibrosis. *J Pediatr* 2004;145:322-6.
80. Lai H, Farrell PM, FIRST Study Group. Variability of fecal elastase during infancy: potential impact on its utility as a secondary criterion for CF newborn screening program [Abstract]. *Pediatr Pulmonol* 2016;51(Suppl 45). In press.
81. Ooi CY, Castellani C, Keenan K, Avolio J, Volpi S, Boland M, et al. Inconclusive diagnosis of cystic fibrosis after newborn screening. *Pediatrics* 2015;135:e1377-85.
82. Sermet-Gaudelus I, Girodon E, Roussel D, Deneuve E, Bui S, Huet F, et al. Measurement of nasal potential difference in young children with an equivocal sweat test following newborn screening for cystic fibrosis. *Thorax* 2010;65:539-44.
83. Hirtz S, Gonska T, Seydewitz HH, Thomas J, Greiner P, Kuehr J, et al. CFTR Cl⁻ channel function in native human colon correlates with the genotype and phenotype in cystic fibrosis. *Gastroenterology* 2004;127:1085-95.
84. De Jonge HR, Ballmann M, Veeze H, Bronsveld I, Stanke F, Tümmler B, et al. Ex vivo CF diagnosis by intestinal current measurements (ICM) in small aperture, circulating Ussing chambers. *J Cyst Fibros* 2004;3(Suppl 2):159-63.
85. Clancy JP, Szczesniak RD, Ashlock MA, Ernst SE, Fan L, Hornick DB, et al. Multicenter intestinal current measurements in rectal biopsies from CF and non-CF subjects to monitor CFTR function. *PLoS ONE* 2013;8:e73905.
86. Derichs N, Pinders-Kessler L, Bronsveld I, Scheinert S, Rückes-Nilges C, de Jonge H, et al. Multicenter European standardization and reference values for intestinal current measurement in rectal biopsies. [Abstract]. *Pediatr Pulmonol* 2013;48(Suppl 36):300.
87. Derichs N, Sanz J, Von Kanel T, Stolpe C, Zapf A, Tümmler B, et al. Intestinal current measurement for diagnostic classification of patients with questionable cystic fibrosis: validation and reference data. *Thorax* 2010;65:594-9.
88. Sousa M, Servidoni MF, Vinagre AM, Ramalho AS, Bonadia LC, Felício V, et al. Measurements of CFTR-mediated Cl⁻ secretion in human rectal biopsies constitute a robust biomarker for Cystic Fibrosis diagnosis and prognosis. *PLoS ONE* 2012;7:e47708.
89. Matecki S, Kent L, de Boeck K, Le Bourgeois M, Zielen S, Braggion C, et al. Is the raised volume rapid thoracic compression technique ready for use in clinical trials in infants with cystic fibrosis? *J Cyst Fibros* 2016;15:10-20.
90. Anagnostopoulou P, Egger B, Lurà M, Usemann J, Schmidt A, Gorlanova O, et al. Multiple breath washout analysis in infants: quality assessment and recommendations for improvement. *Physiol Meas* 2016;37:L1-15.
91. Lum S, Gustafsson P, Ljungberg H, Hülskamp G, Bush A, Carr SB, et al. Early detection of cystic fibrosis lung disease: multiple-breath washout versus raised volume tests. *Thorax* 2007;62:341-7.
92. Kieninger E, Singer F, Fuchs O, Abbas C, Frey U, Regamey N, et al. Long-term course of lung clearance index between infancy and school age in cystic fibrosis subjects. *J Cyst Fibros* 2011;10:487-90.
93. Sly PD, Gangell CL, Chen L, Ware RS, Ranganathan S, Mott LS, et al. Risk factors for bronchiectasis in children with cystic fibrosis. *N Engl J Med* 2013;368:1963-70.
94. Thia LP, Calder A, Stocks J, Bush A, Owens CM, Wallis C, et al. Is chest CT useful in newborn screened infants with cystic fibrosis at 1 year of age? *Thorax* 2014;69:320-7.
95. Oppenheimer EH, Esterly JR. Pathology of cystic fibrosis review of the literature and comparison with 146 autopsied cases. *Perspect Pediatr Pathol* 1975;2:241-78.

96. Blau H, Linnane B, Carzino R, Tannenbaum E-L, Skoric B, Robinson PJ, et al. Induced sputum compared to bronchoalveolar lavage in young, non-expectorating cystic fibrosis children. *J Cyst Fibros* 2014;13:106-10.
97. Marcus MS, Sondel SA, Farrell PM, Laxova A, Carey PM, Langhough R, et al. Nutritional status of infants with cystic fibrosis associated with early diagnosis and intervention. *Am J Clin Nutr* 1991;54:578-85.
98. Bronstein MN, Sokol RJ, Abman SH, Chatfield BA, Hammond KB, Hambidge KM, et al. Pancreatic insufficiency, growth, and nutrition in infants identified by newborn screening as having cystic fibrosis. *J Pediatr* 1992;120(4 Pt 1):533-40.
99. Ballesteros Y, Hernandez MI, Rojo P, Manzanares J, Nebreda V, Carbajosa H, et al. Hyponatremic dehydration as a presentation of cystic fibrosis. *Pediatr Emerg Care* 2006;22:725-7.
100. Cystic Fibrosis Foundation, Borowitz D, Robinson KA, Rosenfeld M, Davis SD, Sabadosa KA, et al. Cystic Fibrosis Foundation evidence-based guidelines for management of infants with cystic fibrosis. *J Pediatr* 2009;155(Suppl 6):S73-93.
101. Castellani C, Macek M, Cassiman J-J, Duff A, Massie J, ten Kate LP, et al. Benchmarks for cystic fibrosis carrier screening: a European consensus document. *J Cyst Fibros* 2010;9:165-78.
102. Tluczek A, Zaleski C, Stachiw-Hietpas D, Modaff P, Adamski CR, Nelson MR, et al. A tailored approach to family-centered genetic counseling for cystic fibrosis newborn screening: the Wisconsin model. *J Genet Couns* 2011;20:115-28.
103. Knapp EA, Fink AK, Goss CH, Sewall A, Ostrenga J, Dowd C, et al. The Cystic Fibrosis Foundation Patient Registry. Design and methods of a national observational disease registry. *Ann Am Thorac Soc* 2016;13:1173-9.

Appendix

Case Study 1

A 1-week-old female infant presents to the pediatrician for a first visit following an uneventful pregnancy and normal vaginal delivery. She has been steadily improving in the time that she breastfeeds and is currently now at birth weight

after being several ounces down at her discharge on day 2.

Parents are concerned that she sneezes and has some nasal stuffiness. The physical examination is within normal limits.

She was born in a state that uses IRT/DNA for CF NBS and was positive for 2 mutations: c.350G>A mutation (legacy: R117H) and c.1521_1523delCTT (legacy: F508del). The polyT intron analysis revealed 7T/7T.

What is the recommended next step by the pediatrician for the evaluation of this infant?

-
- A. Referral to a CF center for evaluation and sweat chloride testing
 - B. Observe for 1 year and refer to CF center if clinical symptoms suggestive of CF develop
 - C. Send for detailed genetic analysis of CF gene
 - D. Send for sweat testing at accredited laboratory and observe for 1 year of life with referral to CF center if symptoms develop

A—correct

A sweat test is obtained at an accredited laboratory, and sweat chloride value is

33 mmol/L. The infant was seen at an accredited CF center where a negative history was obtained, and she had a normal physical examination.

What is the most likely diagnosis of this infant at this time?

-
- A. CF
 - B. CRMS/CFSPID
 - C. Atypical CF
 - D. CFTR-related disorder

B—correct

The diagnosis of CRMS or CFSPID is given after a positive newborn screen and: a sweat test value less than 30 mmol/L and 2 CFTR mutations, at least 1 of which has unclear phenotypic consequences; or an intermediate sweat chloride value (30-59 mmol/L) and 1 or no CF-causing mutations. In this infant, the R117H with 7T is the mutation that is unclear in its clinical significance but in a few patients has been associated with the development of symptoms consistent with CF. The term CRMS/CFSPID is reserved for those screen-positive infants without clinical features consistent with CF. Following consensus guidelines from 2008 would have resulted in considering this infant not to have CF, and no follow-up would be recommended. The new guidelines are specific that this infant should receive an evaluation and education at an accredited CF center. This is a significant shift in guidance.

Children designated as CRMS/CFSPID should undergo at least 1 repeat sweat chloride test at a CF center with suitable expertise, such as an accredited CF center. This is often done when the infant is 6 months of age. Some centers repeat again at 2 years of age.

These infants and children may benefit from continued clinical evaluation by CF providers at the accredited CF centers along with regular care from their primary care providers to monitor for signs and symptoms of CF. A minority of these infants may develop changes in their physiologic testing along with clinical symptoms that ultimately lead to a diagnosis of CF.

	Sweat Cl ⁻	Sweat Cl ⁻	Sweat Cl ⁻
	<30 mmol/L	= 30-59 mmol/L	≥60 mmol/L
Mutation 1	Mutation 2		
CF-causing	CF-causing	CF	CF
CF-causing	MVCC	CRMS/CFSPID	CRMS/CFSPID
CF-causing	Unknown	CRMS/CFSPID	CRMS/CFSPID
	significance		CF
	(not in		
	CFTR2)		
Not available	Not available	CF unlikely	CRMS/CFSPID
			CF

Case Study 2

A 1-week-old male infant presents for his first visit to the primary care physician. He was born at 34 weeks' gestation and was screen-positive because of high IRT and 1 CF-causing mutation, F508del, on his CF newborn screen test. During this visit, he is noted to be feeding well and is a few ounces over his birthweight of 4 pounds (1.8 kg). His history is negative for respiratory symptoms, and there is no family history of cystic fibrosis.

His physician refers him to the local hospital for a sweat chloride test as per protocol. At 9 days of age, the test is completed, and results in quantity not sufficient for testing (QNS).

What is the next step for this infant?

Guide to initial diagnosis in cases where 2 mutations have been identified through NBS or no genes identified in IRT/ IRT CF NBS algorithm:

- A. Repeat testing when he is corrected 36 wk of age and is 2 kg in weight
- B. Repeat testing at an accredited laboratory
- C. Repeat testing when tolerating feedings and is well hydrated
- D. All of the above

D—correct

The sweat test was performed when his weight reached 2 kg and was normal with a sweat chloride value of 12 mmol/L. The infant is considered to be a carrier for CF.

What should be done next for this infant?

-
- A. Discuss the testing results with the parents and refer for genetic counseling
 - B. Repeat the sweat test at 6 mo of age
 - C. Send for expanded genetic mutation analysis
 - D. Refer all siblings for sweat testing to verify the negative result

A—correct

Newborns with a positive CF NBS test should be tested when at least 36 wk gestation and 2 kg body weight. Testing should be completed no later than 10-28 d of age at an accredited laboratory in a healthy full term newborn

Diagnosis of Cystic Fibrosis in Screened Populations

with a positive CF NBS test.

In this case, the carrier state was detected by CF NBS testing. The incidence of carrier testing has been found to be decreased in those states that use the sequence of IRT/IRT/DNA testing. Genetic counseling is recommended for the families of all infants that screen positive for CF including those with carrier status.

It is important to recognize that CF NBS testing, except perhaps for those areas that use IRT/expanded DNA testing, is not designed to detect the carrier state. A negative NBS test in the majority of cases does not exclude that the infant is a carrier of CF.

Case Study 3

A female infant was born at 38 weeks' gestation with a birth weight of 2.8 kg to African American parents. Prenatal screening for CFTR carrier status revealed that the mother carried a common disease-causing CFTR mutation—c.1652G>A

S44.e1

(legacy: G551D). The father was tested via a 23-mutation panel (American College of Obstetricians and Gynecologists) that detected common mutations and was found to have no mutations.

The infant had a positive CF NBS test with an elevated IRT and was positive for 1 mutation—G551D. She was followed by her primary care physician, and at 2 weeks of age, she was found to be breastfeeding well but the weight had decreased to 2.3 kg. A sweat test was ordered and had QNS for analysis. At 4 weeks of age, she was seen again and weighed 2.2 kg, and a repeat sweat test was again QNS. A third sweat test at 6 weeks of age was positive with results of 89 and 94 mmol/L.

She was then seen at a CF center and was started on pancreatic enzyme replacement therapy, albuterol, and chest physiotherapy. Further testing was completed. Fecal pancreatic elastase was low at <15 mg/g. She was found to have her mother's mutation as well as a rare second disease-causing mutation that her father had not been tested for during prenatal testing. Slow weight gain was then established during a subsequent visit to the CF center and her primary care physician.

At 3 months of age, the infant presented to an emergency department for poor feeding. She was noted to have a 3-day history of reduced oral intake and irritability without cough or rhinorrhea. Over the previous 24 hours, she had eaten very little by mouth and had only 2 wet diapers. On physical examination, she was afebrile but lethargic and had dry tacky mucous membranes. Her weight was at the first percentile for

age. Her chest was clear, and her abdomen was soft and nontender.

The most likely etiology of the current findings in this infant with CF is:

-
- A. Chronic malnutrition
 - B. Acute pulmonary exacerbation of CF
 - C. Distal intestinal obstruction syndrome
 - D. Electrolyte abnormalities

D—correct

This infant presents with acute changes in behavior and feeding suggestive of electrolyte abnormalities; she had not been prescribed supplemental salt, a recommendation of the CF Foundation clinical practice guidelines for infants with CF. A basic metabolic panel showed Na⁺ 119 mEq/L (134-146); K⁺ 1.9 mEq/L (4.2-6.4); Cl⁻ <60 mEq/L (98-108); HCO₃⁻ 49.6 mEq/L (23-30). An electrocardiogram revealed first degree atrioventricular block and a prolonged QTc interval. She was hospitalized in the intensive care unit for 1 wk and was hospitalized for a total of 4 wk.

This case illustrates risk factors for delayed diagnosis after a positive CF NBS. Because the infant was from a racial minority with a lower incidence of CF, and because her mother was a carrier of a *CFTR* gene mutation but her father was found to have a "negative" carrier test, her initial positive NBS test was thought to be reflective of a carrier status. Even though sweat testing was ordered within an appropriate time interval, the QNS values were thought to be due to inadequate weight gain, and she was not evaluated for the possibility that pancreatic insufficiency was the underlying cause of this poor postnatal weight gain.

Her diagnosis was delayed until after the first month of life and, in addition, salt was not prescribed. She subsequently developed a severe, life-threatening electrolyte imbalance and notably this occurred during the winter in a cold climate. In infants with a positive newborn screen and poor growth, it is appropriate to make a "presumptive diagnosis" of CF, perform appropriate diagnostic studies, and treat empirically with pancreatic enzyme replacement therapy and salt until the diagnosis can be either confirmed or ruled out.
